Actos Generics Should Await Expiration Of All Patented Uses, Takeda Tells FDA
Approving generic versions of Takeda's Actos for use as monotherapy prior to expiration of its combination-use patents would hinder the safe and effective use of the diabetes drug, the firm says in a petition to FDA
You may also be interested in...
As an interim step in its ongoing review of thiazolidinedione cardiac safety, FDA has called for revised class labeling for the TZDs featuring strengthened warnings about the incidence of heart failure and contraindications for patients with existing heart failure
The recently passed House FDA reform bill (H.R. 2900) includes several last-minute changes that bring it closer to the Senate version (S. 1082), suggesting Congressional efforts to ease the prospective merge of the bills in the upcoming Conference Committee
The International Fragrance Association North America took a break from its higher-stakes advocacy work Nov. 1 to give lawmakers and congressional staffers a "scent experience." Perfumers from six of the group's biggest members were on hand with "Scents of Home," joined by Monell Center researchers to educate attendees on the mechanics of scent and the important role it plays in people's lives.